JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some “real de-risking clinical data to comfortably” value Acrivon’s biomarker-based selection platform.

Confident Investing Starts Here:

Quickly and easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACRV:

Disclaimer & DisclosureReport an Issue

Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating Acrivon Therapeutics Reports Q1 2025 Progress and Financials Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)

View Comments